Correlates of vaccine protection from influenza and its complications
- 1 January 2012
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (1) , 34-44
- https://doi.org/10.4161/hv.8.1.18214
Abstract
Despite use of influenza vaccines for more than 65 y, influenza and its complications are a major cause of morbidity and mortality worldwide. Most deaths during influenza virus infections are due to underlying co-morbidities or secondary bacterial pneumonia. The measures of immune response currently used for licensure of influenza vaccines are relevant mainly for protection from viral infection in healthy adults. Development of new or improved influenza vaccines will require a definition of novel, and specific correlates of protection. These correlates should associate immune responses with outcomes that are relevant to specific risk groups, such as asthma exacerbation, hospitalization or disruptions to care or daily activities. Assessment of vaccine effectiveness for both viral and bacterial vaccines should include measures of impact on secondary bacterial pneumonia.Keywords
This publication has 123 references indexed in Scilit:
- Inactivated and live, attenuated influenza vaccines protect mice against influenza:Streptococcus pyogenes super-infectionsVaccine, 2011
- Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccineJournal of Allergy and Clinical Immunology, 2010
- Influenza Enhances Susceptibility to Natural Acquisition of and Disease due toStreptococcus pneumoniaein FerretsThe Journal of Infectious Diseases, 2010
- The need for quadrivalent vaccine against seasonal influenzaVaccine, 2010
- A multi-valent vaccine approach that elicits broad immunity within an influenza subtypeVaccine, 2009
- Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virusVaccine, 2008
- Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategiesProceedings of the National Academy of Sciences, 2008
- Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvantVaccine, 2007
- The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesEpidemiology and Infection, 1972
- A VIRUS OBTAINED FROM INFLUENZA PATIENTSThe Lancet, 1933